(NASDAQ: PCVX) Vaxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.99%.
Vaxcyte's earnings in 2026 is -$946,532,000.On average, 12 Wall Street analysts forecast PCVX's earnings for 2026 to be -$1,234,744,579, with the lowest PCVX earnings forecast at -$1,388,210,435, and the highest PCVX earnings forecast at -$943,061,261. On average, 12 Wall Street analysts forecast PCVX's earnings for 2027 to be -$985,340,902, with the lowest PCVX earnings forecast at -$1,623,116,584, and the highest PCVX earnings forecast at -$233,491,052.
In 2028, PCVX is forecast to generate -$966,193,770 in earnings, with the lowest earnings forecast at -$1,621,701,487 and the highest earnings forecast at -$738,377,547.